Datasheet for ABIN1702764
anti-GCS1 antibody (AA 51-150) (Cy3)

## Overview

| Quantity: | $100 \mu \mathrm{~L}$ |
| :--- | :--- |
| Target: | GCS1 (MOGS) |
| Binding Specificity: | AA 51-150 |
| Reactivity: | Human |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This GCS1 antibody is conjugated to Cy3 |
| Application: | Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence |
|  | (Paraffin-embedded Sections) (IF (p)) |

## Product Details

| Immunogen: | KLH conjugated synthetic peptide derived from human GCS1 |
| :--- | :--- |
| Isotype: | IgG |
| Predicted Reactivity: | Human,Mouse,Rat,Dog |
| Purification: | Purified by Protein A. |
| Target Details |  |
| Target: | GCS1 (MOGS) |
| Alternative Name: | GCS1 (MOGS Products) |
| Background: | Synonyms: EC 3.2.1.106, glucosidase I, Mannosyl oligosaccharide glucosidase, Mannosyl- |


|  | oligosaccharide glucosidase, Mogs, MOGS_HUMAN, Processing A glucosidase I, Processing Aglucosidase I. |
| :---: | :---: |
|  | Background: Glycosylation of asparagine residues in Asn-X-Ser/Thr motifs in proteins |
|  | commonly occur in the lumen of the endoplasmic reticulum (ER). Glucosidase I catalyzes the |
|  | first step in the N -linked oligosaccharide processing pathway. It specifically removes the distal |
|  | alpha 1,2-linked glucose residue from the Glc3-Man9-GICNAc2 oligosaccharide precursor. |
|  | Glucosidase I contains a short cytosolic tail, a single pass transmembrane domain and a large |
|  | C-terminal catalytic domain located on the luminal side of the ER. Mutations in the gene |
|  | encoding Glucosidase I result in the congenital disorder glycosylation (CDG-IIb), which is |
|  | characterized by generalized hypotonia, dysmorphic features, hepatomegaly, hypoventilation, |
|  | feeding problems, seizures and death. Two point mutations in the Glucosidase I gene have |
|  | been identified and result in amino acid substitutions, namely Arg486Thr and Phe652Leu, that |
|  | affect polypeptide folding and active site formation. |
| Gene ID: | 7841 |
| Pathways: | SARS-CoV-2 Protein Interactome |
| Application Details |  |
| Application Notes: | IF(IHC-P) 1:50-200 |
|  | IF(IHC-F) 1:50-200 |
|  | IF(ICC) 1:50-200 |
| Restrictions: | For Research Use only |
| Handling |  |
| Format: | Liquid |
| Concentration: | $1 \mu \mathrm{~g} / \mu \mathrm{L}$ |
| Buffer: | Aqueous buffered solution containing 0.01M TBS ( pH 7.4 ) with $1 \%$ BSA, $0.03 \%$ Proclin300 and |
|  | $50 \%$ Glycerol. |
| Preservative: | ProClin |
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only. |
| Storage: | $-20^{\circ} \mathrm{C}$ |
| Storage Comment: | Store at $-20^{\circ} \mathrm{C}$. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |

